Biosimilar Pipeline 2H 2025

IPD Analytics has released its Biosimilar Pipeline Report for 2H 2025, providing an outlook for potential approvals and launches across the biosimilar landscape over the 2025–2028 horizon. In addition, the report examines trends in average sales prices of reference products, biosimilar approvals, and changes to FDA interchangeability guidance.

Subscribers can use this report as a companion to our online Clinical Development Tracker within our Payer & Provider Insights platform, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. In tandem, these reports deliver insight into trending classes that will affect the competitive landscape and drug spend.